|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Several other cell surface tumor antigens, such as CD20 and CD22, found in the majority of leukemias and lymphomas are considered potential targets by pharmaceutical companies and research organizations, and trials have been ongoing in this direction.
|
31578576 |
2019 |
|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
|
29922424 |
2018 |
|
Lymphoma
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Since latest generation immunotoxins are composed of a toxic domain genetically fused to antibody fragment(s) which confer on the IT target selective specificity, we rescued from the hydridoma 4KB128, a recombinant single-chain variable fragment (scFv) targeting CD22, a marker antigen expressed by B-lineage leukaemias and lymphomas.
|
25889802 |
2015 |
|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
To address these issues, we have demonstrated that chemically self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 ε subunit of the T-cell-receptor/CD3 complex and the CD22 antigen on malignant B cells such as B-leukemias or lymphomas.
|
26230248 |
2015 |
|
Lymphoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
C61-LNP plus low dose TBI also yielded progression-free survival, tumor-free survival and overall survival outcomes in CD22ΔE12 × BCR-ABL double transgenic mice with advanced stage, radiation-resistant BPL with lymphomatous features that were significantly superior to those of mice treated with TBI alone or C61-LNP alone.
|
26285772 |
2015 |
|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
These data support the testing of RFB4(dsFv)-PE38 in patients with CD22+ leukemias and lymphomas, which is presently under way.
|
10778980 |
2000 |
|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
|
8643111 |
1995 |
|
Lymphoma
|
0.090 |
Biomarker
|
group |
BEFREE |
These lymphomas have a perifollicular growth pattern and IgM+, IgD+, CD10-, and CD22+ immunophenotype features typical of non-follicle center cell lymphomas and probably belong to the follicle mantle lymphomas described recently.
|
2065296 |
1991 |
|
Lymphoma
|
0.090 |
AlteredExpression
|
group |
BEFREE |
With the exception of some lymphoblastic lymphomas, high-grade B-cell lymphomas normally expressed the pan B-cell antigens CD19 and CD22 but only immunoblastic lymphomas consistently expressed the pan B marker CD20.
|
3509751 |
1987 |